Site notifications

Sub menu

 

 

Merck Sharp & Dohme (Australia) Pty Limited

Regulatory activities for this sponsor.

Type

Date

6 result(s) found, displaying 1 to 6

  • AusPAR: Keytruda

    Australian public assessment report (AusPar)
    AusPAR for Keytruda (pembrolizumab) for the treatment of triple-negative breast cancer.

  • Welireg

    Prescription medicine decision summary
    Welireg (belzutifan) is approved to treat adult patients with von Hippel-Lindau (VHL) disease

  • AusPAR: Molnupiravir

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Molnupiravir

  • AusPAR: Pembrolizumab (rch)

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Pembrolizumab (rch)

  • AusPAR: Ezetimibe/Atorvastatin

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Ezetimibe/Atorvastatin